US20040023414A1 - Self-assembling peptide surfaces for cell patterning and interactions - Google Patents

Self-assembling peptide surfaces for cell patterning and interactions Download PDF

Info

Publication number
US20040023414A1
US20040023414A1 US10/317,838 US31783802A US2004023414A1 US 20040023414 A1 US20040023414 A1 US 20040023414A1 US 31783802 A US31783802 A US 31783802A US 2004023414 A1 US2004023414 A1 US 2004023414A1
Authority
US
United States
Prior art keywords
peptides
solid support
cells
peptide
self
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/317,838
Inventor
Shuguang Zhang
Alexander Rich
Lin Yan
George Whitesides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Massachusetts Institute of Technology
Original Assignee
Harvard College
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Massachusetts Institute of Technology filed Critical Harvard College
Priority to US10/317,838 priority Critical patent/US20040023414A1/en
Publication of US20040023414A1 publication Critical patent/US20040023414A1/en
Priority to US11/068,936 priority patent/US20060019309A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00Nanotechnology for materials or surface science, e.g. nanocomposites
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00Manufacture or treatment of nanostructures
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14Peptides being immobilised on, or in, an inorganic carrier
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2/00Peptides of undefined number of amino acids; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068General culture methods using substrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • GPHYSICS
    • G03PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03FPHOTOMECHANICAL PRODUCTION OF TEXTURED OR PATTERNED SURFACES, e.g. FOR PRINTING, FOR PROCESSING OF SEMICONDUCTOR DEVICES; MATERIALS THEREFOR; ORIGINALS THEREFOR; APPARATUS SPECIALLY ADAPTED THEREFOR
    • G03F7/00Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printing surfaces; Materials therefor, e.g. comprising photoresists; Apparatus specially adapted therefor
    • G03F7/0002Lithographic processes using patterning methods other than those involving the exposure to radiation, e.g. by stamping
    • GPHYSICS
    • G03PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03FPHOTOMECHANICAL PRODUCTION OF TEXTURED OR PATTERNED SURFACES, e.g. FOR PRINTING, FOR PROCESSING OF SEMICONDUCTOR DEVICES; MATERIALS THEREFOR; ORIGINALS THEREFOR; APPARATUS SPECIALLY ADAPTED THEREFOR
    • G03F7/00Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printing surfaces; Materials therefor, e.g. comprising photoresists; Apparatus specially adapted therefor
    • G03F7/16Coating processes; Apparatus therefor
    • G03F7/165Monolayers, e.g. Langmuir-Blodgett
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00351Means for dispensing and evacuation of reagents
    • B01J2219/00382Stamping
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00612Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports the surface being inorganic
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00614Delimitation of the attachment areas
    • B01J2219/00617Delimitation of the attachment areas by chemical means
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00614Delimitation of the attachment areas
    • B01J2219/00617Delimitation of the attachment areas by chemical means
    • B01J2219/00619Delimitation of the attachment areas by chemical means using hydrophilic or hydrophobic regions
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00623Immobilisation or binding
    • B01J2219/00626Covalent
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00623Immobilisation or binding
    • B01J2219/0063Other, e.g. van der Waals forces, hydrogen bonding
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00632Introduction of reactive groups to the surface
    • B01J2219/00635Introduction of reactive groups to the surface by reactive plasma treatment
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00632Introduction of reactive groups to the surface
    • B01J2219/00637Introduction of reactive groups to the surface by coating it with another layer
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00659Two-dimensional arrays
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718Type of compounds synthesised
    • B01J2219/0072Organic compounds
    • B01J2219/00725Peptides
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718Type of compounds synthesised
    • B01J2219/0072Organic compounds
    • B01J2219/0074Biological products
    • B01J2219/00743Cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2535/00Supports or coatings for cell culture characterised by topography
    • C12N2535/10Patterned coating
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/10Libraries containing peptides or polypeptides, or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B60/00Apparatus specially adapted for use in combinatorial chemistry or with libraries
    • C40B60/14Apparatus specially adapted for use in combinatorial chemistry or with libraries for creating libraries
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2610/00Assays involving self-assembled monolayers [SAMs]

Definitions

  • SAMs Self-assembled monolayers
  • a monolayer of organic compounds with reactive moieties onto a solid support under conditions wherein the compounds react with and bind to the solid support in a single ordered and patterned layer.
  • Lopez, et al. “Convenient Methods for Patterning the Adhesion of Mammalian Cells to Surfaces Using Self-Assembled Monolayers of Alkanethiolates on Gold,” J. Am. Chem.
  • SAMs can be used to pattern cells on a surface by presenting chemical moieties which bind to the cells on the solid surface. Mrksich and Whitesides, above. However, these molecules, and the resulting SAMs, can be difficult and/or expensive to manufacture. Thus, improvements and cost reductions in the manufacture of SAMs are desirable and are necessary.
  • This invention is based upon the discovery that improved SAMs can be manufactured by imprinting reactive self assembling peptides onto solid supports.
  • the SAMs are characterized by ease of manufacture and purification. They are versatile in their ability to readily provide a large variety of chemical reactive moieties, or “presenting groups”, to selected targets.
  • the SAM's of the present invention can be readily designed to present ligands to cellular receptors, cell adhesion motifs, antibodies or antigen-binding fragments thereof to cell surface proteins.
  • This preferred class of SAMs can be used to bind a target, e.g. a selected cell or cells, to a predetermined locus on the solid support.
  • the invention relates to a composition of matter comprising a solid support and a self-assembled monolayer of linear peptides wherein said peptides bound directly to said solid support through a terminal amino acid in a predetermined pattern.
  • the peptides comprise a terminal reactive group, a central linker and a presenting group.
  • the invention also relates to the uses and applications of the SAMs described herein, as will be described in more detail below.
  • the invention further relates to a method for manufacturing an SAM, or a composition of matter comprising a solid support and a self-assembled monolayer of linear peptides wherein said peptides bound directly to said solid support through a terminal amino acid in a predetermined pattern, comprising microcontact printing the reactive peptides onto the solid support and maintaining the peptides under conditions suitable for binding.
  • FIGS. 1 and 2 illustrate methods of microcontact printing reactive peptides to a solid support in a predetermined pattern.
  • FIG. 3 illustrates patterns which may be selected, for example, in SAMs for immobilizing cells.
  • the invention relates to improved SAMs comprising a predetermined pattern of peptides on a solid support.
  • Preferred peptides of the invention can be characterized by three regions bound to each other through an amino acid or via peptide binding, the “terminal reactive group”, the “central linker” and the “presenting group.”
  • the peptides Upon binding the peptides to the solid support, the peptides are preferably highly ordered and preferably possess a consistent linear and parallel configuration with each other. Generally, the peptides, or the central linker thereof, are fully extended beta strands in configuration under the conditions of use.
  • the peptides are linear (e.g., free or substantially free of branching or tertiary structure). “Substantially free” of branching or tertiary structure is intended to include minor amounts of branching and peptide interactions which do not significantly interfere with the free movement or function of the presenting group.
  • peptides “substantially free” of branching may include a peptide composition wherein less than about 5% of the peptides are characterized by one or more branches.
  • the length of the peptide is not critical to the invention, the peptide is preferably small to moderate in length.
  • the central linker of the peptide can preferably be between about 2 to about 50 naturally occurring or non-naturally occurring amino acids in length are preferred, more preferably between about 8 to about 35 amino acids in length.
  • Certain peptides in excess of 50 may present undesirable interactions of the peptides, such as a possible tendency of the peptide to fold.
  • Peptide interactions can be predicted by, for example, computer modeling and structural information available at protein data banks at, for example, Brookhaven National Laboratories, N.Y.
  • Peptides which can be used in the invention can be characterized by a reactive moiety which can react and bind to the solid support, the “terminal reactive group”.
  • the terminal reactive group is an amino acid characterized by a functional group pendant from the side chain, the amino group or the carboxy group.
  • the terminal reactive group which binds to the solid support can be an amino acid substituted by a hydroxy, thiol, carboxy, amino, amido, imido or guanidino group.
  • Preferred terminal amino acids thus, include serine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine and histidine.
  • the terminal reactive group can be a normaturally-occurring amino acid characterized by a functionality which can react with the solid support.
  • examples include beta amino acids (amino acids wherein the amino and/or carboxy group are not substituted on the same alpha carbon, such as beta-alanine) or amino acids which have been chemically modified, by electrophilic substitution, nucleophilic substitution, activation reactions or addition reactions, for example. See March, “Advanced Chemistry,” Third Edition (1985), Chapters 10-16, the contents of which are incorporated herein by reference.
  • the peptide be of sufficient length to provide a flexible, spatial separation between the solid support (upon reaction with the reactive terminal group) and the opposing reactive terminus of the peptide (e.g., the presenting group).
  • the peptides of the invention preferably comprise a “central linker”, which is a peptide bound to the terminal reactive group and presenting group through peptide or amide bonds.
  • the amino acids employed in the peptide and/or central linker are selected to promote or optimize a beta strand configuration at the conditions for use. It is further preferred that the amino acids in this portion of the peptide be substantially free of large or bulky side chains or bonds which will interfere with the configuration (e.g. proline).
  • the amino acids can further be selected considering material strength, permeability and degradation rate of the resulting peptide and SAM.
  • the amino acids selected for the central section of the peptide are glycine, L-alanine and D-alanine.
  • D-amino acids have advantages in many applications due to their resistance to L-protease degradation.
  • the length of the central linker where present is also generally not critical to the invention.
  • the central linker is between about 2 and about 30 amino acids in length, more preferably between about 2 and about 8 amino acids.
  • the peptide can also be characterized by a “presenting moiety” which will bind to one or more targets.
  • presenting group is defined herein to include one or more chemical atoms, functional groups, amino acids or peptides that possess an affinity to or resistance for a target entity.
  • a presenting group which presents a resistance for a target entity e.g., a protein or cell, can be poly(ethylene glycol) or another compound which is inert to the target.
  • a presenting group which is resistant to water, as a target molecule is a hydrophobic group, such as a high chain alkyl or hydrophobically blocked amino acid (e.g., an alkyl ester of valine, leucine, isoleucine or phenylalanine).
  • a hydrophobic group such as a high chain alkyl or hydrophobically blocked amino acid (e.g., an alkyl ester of valine, leucine, isoleucine or phenylalanine).
  • one or more peptides employed in the present invention possess a presenting group with an affinity for a target, e.g. a target molecule.
  • the presenting group can be specific or non-specific for the target molecule.
  • the target is a cell
  • the target molecule can be a cell surface protein.
  • the presenting group can be a ligand for that protein, an antibody or an antigen-binding fragment thereof which binds specifically to the cell surface protein.
  • the presenting group can be a non-peptide or, preferably, a peptide. As discussed above, the presenting group can be a ligand for or an antibody or antibody fragment which binds to the target molecule.
  • Particularly suitable presenting groups are oligopeptides which self assemble to form a beta sheet under conditions for the desired or selected application.
  • oligopeptides which self assemble under these conditions are described in U.S. application Ser. Nos. 08/346,849 and 08/784,606, which are incorporated herein by reference in their entireties. Briefly, these oligopeptides are amphiphilic, have alternating hydrophobic and hydrophilic amino acids and are complementary.
  • particularly preferred oligopeptides for self assembly are RADX n and EAKX n wherein X is an amino acid and n is an integer between about 2 and about 8.
  • Particularly preferred targets include cells.
  • Examples of cells which can be targeted include prokaryotic and eukaryotic cells.
  • the cells can be mammalian, plant, bacterial, and yeast. Mammalian cells which can be targeted include tumor cells, normal somatic cells and stem cells.
  • the cells can be fibroblasts, endothelial cells, neuronal cells, hepatocytes, blood cells, smooth muscle cells, and progenitors thereof, for example.
  • Bacterial cells can be gram positive or gram negative bacteria and can include Escherichia coli , Streptococcus, Staphylococcus, as well as many others.
  • Bacterial cells which may be desirable to target and, thus detect and/or culture, can include pathogens and non-pathogens, e.g., contaminants in a food sample, a mammalian tissue sample or serum sample or in a plant tissue sample.
  • pathogens and non-pathogens e.g., contaminants in a food sample, a mammalian tissue sample or serum sample or in a plant tissue sample.
  • yeast can be targeted and include, for example, Candida and Saccharomyces.
  • Cells can preferably be targeted by selecting a presenting group which will react with and bind to the cell surface. Generally, this is accomplished by binding to a cell surface molecule, such as a protein, lipid, or sugar at the surface of the protein. These surface molecules are included herein as “target molecules.”
  • a target molecule can be a cell surface protein and can be specific to the target or, in this case, cell, or the target molecule can be non-specific.
  • the object of the application is to detect the presence of a cell in a sample, e.g., a tumor cell in a sample which can contain normal cells, it is desirable that the target molecule be specific to the tumor cell (e.g., present on tumor cells and absent on the normal cells).
  • tumor markers are generally known in the art as tumor markers.
  • the object of the invention is to detect the presence of bacteria in a sample, such as in food, tissue sample, blood sample, or pharmaceutical, it can be desirable to select a target molecule which is present on many types of bacteria which are potentially contaminating the sample to be tested. In other instances, e.g., where a substantially pure cell culture is being targeted or transferred to the solid support, the selection of specific or non-specific target molecule is immaterial.
  • Suitable target molecules include tumor markers, cellular receptors, such as CD4 and, CD8.
  • Neuronal cellular receptors include N-CAMs, the L1 receptors, NGF receptor, the netrin receptor and others.
  • Targets can include non-cellular products as well, including viruses (such as retroviruses, influenza viruses, and herpesviruses, for example), and proteins (such as prostate soluble antigen (PSA), cytokines, cytokine receptors, growth factors, and growth factor recpetors.
  • viruses such as retroviruses, influenza viruses, and herpesviruses, for example
  • proteins such as prostate soluble antigen (PSA), cytokines, cytokine receptors, growth factors, and growth factor recpetors.
  • PSA prostate soluble antigen
  • cytokines cytokine receptors
  • growth factors growth factors
  • growth factor recpetors a virus
  • the target molecule can be a surface protein as well, such as a cellular receptor implicated in the infection of cells.
  • a particularly preferred target molecule for HIV is, for example, gp120.
  • Examples of presenting groups include cellular adhesion motifs, ligands or binding fragments of ligands for the target molecule (e.g., the ligand for gp120 is CD4), antibodies or antigen binding fragments of antibodies which bind to the target molecule.
  • a ligand is defined here to include molecules which are the same as or substantially the same as the native molecule which binds the target molecule.
  • CD4 is a native ligand for the HIV env protein, gp120.
  • the term “ligand” and, thus, the presenting groups include native CD4, a ligand-binding fragment of CD4 (such as, an extracellular domain), and mutations thereof which bind to gp120.
  • the terminal reactive group, central linker and presenting group are preferably arranged linearly with the central linker bonded directly or indirectly to both the reactive group and the presenting group through, e.g., peptide bonds.
  • the peptide has the formula:
  • X is an inert group, such as H, alkyl, alkoxy, alkylthio or dialkylamine, or is a labile or reactive group, such as a thiol, hydroxy, amino, carboxy, acylhalide, carboxy ester, or halide;
  • AA is, independently, the same or different, naturally-occurring or non-naturally-occurring amino acid, and is preferably, glycine, L-alanine or D-alanine;
  • L is a group which binds specifically or non-specifically to a target and is preferably a peptide, such as a ligand, an antibody or an antibody fragment;
  • n is zero or an integer between 1 to about 5;
  • m is an integer of at least about 2 and, preferably, between about 2 and about 50, more preferably between about 2 and about 8.
  • the peptides of the invention can be manufactured by known and industry stadnard peptide synthesis technology.
  • the peptides can be synthesized chemically or recombinantly (e.g. by the expression of a recombinant nucleic acid molecule which encodes the peptide or a precursor thereof).
  • a precursor of the peptide can be particularly beneficial where one or more of the amino acids are non-naturally occurring (e.g. a beta amino acid or an amino acid with a non-naturally occurring side chain).
  • the manufacture of peptides chemically and recombinantly are generally practiced in the art and are described in, for example, U.S. application Ser. Nos. 08/346,849 and 08/784,606 and Ausubel, Current Protocols in Molecular Biology (1997).
  • the peptides can preferably be purified prior to use in the manufacture of the SAMs by standard techniques, including HPLC.
  • the peptides employed in the invention are imprinted or patterned on a solid support.
  • the shape of the solid support is not critical to the invention and can be selected to optimize ease of use in the particular application.
  • the solid support can be substantially spherical (e.g., a bead) or non-spherical, such as in a container (e.g., a petri dish or cup), cylinder or cone, or a substantially flat film, stick, chip or disc, of essentially any size suitable for the ultimate application.
  • the solid support can be porous (as in a membrane) or non-porous (as in a petri dish or container).
  • the material employed in the manufacture of the solid support is not critical as well.
  • the solid support can be an inorganic material such as a metal, including as gold, copper, zinc, silver or nickel or a metal alloy.
  • the solid support can be glass, silica, or silicon oxide.
  • the solid support can be an organic material, such as a polymer or resin, including nylon, poly(ethylene glycol), and polyfluoropolymers. It can be desirable in some embodiments to employ a transparent solid support.
  • the detection of the binding of an opaque target e.g., a cell
  • the solid support is selected with a view towards its ability to react with the terminal reactive group of the peptide.
  • the thiol group e.g., X
  • the hydroxy group e.g., X
  • siloxane under relatively mild conditions.
  • Solid supports which are inert to the peptide can be derivatized to render them reactive.
  • the solid support can be coated with a reactive material, chemically treated (e.g., by electrophilic or nucleophilic substitution reaction, addition reactions, etc.) to introduce reactive groups.
  • the peptides are printed on the solid support, as will be described below.
  • the terms “printed”, “patterned” or “predetermined pattern” are defined herein to mean that the solid support has ordered areas where the peptides are bonded and not bonded to the solid support. That is, a printed or patterned solid support is expressly not intended to include a support with random or substantially homogeneous distribution of the peptide over its entire surface(s). Furthermore, the peptides are printed on the solid support in a single layer in a substantially consistent configuration. Thus, the terms are further not intended to include solid supports wherein peptides are bonded to the solid support via distinct and different functional groups across the same molecule (e.g., distinct cysteine residues in a protein containing multiple cysteines along its sequence).
  • the patterns which can be selected in this invention are not particularly critical.
  • Preferred patterns for SAMs useful as research tools in the study of cell/cell interactions are linear tracks of alternating peptides which can adhere to the cells and inert tracks of solid support or an inert compound bound to the solid support.
  • the orientation of the cell can further be manipulated. That is a thin track can result in the orientation of the cells linearly.
  • FIG. 3 exemplifies suitable patterns.
  • a polymeric or elastomeric stamp 1 e.g. a polydimethylsiloxane stamp
  • a solution 2 containing the peptide in a suitable solvent is contacted or “inked” with a solution 2 containing the peptide in a suitable solvent and then the inked stamp is pressed against the solid support 3 , thereby transferring the peptide solution in a controlled fashion to the solid support 3 .
  • the peptide is then maintained in contact with the solid support 3 under conditions suitable for binding, resulting in a SAM 4 .
  • the solvent is generally removed, for example, by washing (e.g., extraction), evaporation or lyophilization.
  • the patterned SAM thus formed can then be used directly or can be further derivatized, e.g., by subjecting the SAM to a second printing step to ink a different chemical compound thereon.
  • the second chemical compound can preferably be a peptide of the claimed invention or can be different, such as an alkanethiol or poly(ethylene glycol), as described in Mrksich and Whitesides, above.
  • the SAM can be subjected to additional steps which can modify the peptide on the SAM.
  • This embodiment may be desirable where the presenting group (e.g., L) or the chemical bond to the central linker ((AA) m ) is labile under the conditions for binding the peptide to the solid support.
  • the presenting group can be chemically reacted with a peptide precursor bonded directly to the solid support, thereby obtaining a SAM of the present invention.
  • the exposed areas of the solid support for example, by exposing the SAM to ultraviolet light or oxidize the SAM. This can be done to improve the reactivity or eliminate reactivity of the material of the solid support with one or more materials encountered in storage or in use of the SAM.
  • the solid support 3 is stamped with a solution containing a first compound 5 (such as a poly(alkoxyglycothiol)) which can react with the solid support and presents an imprint or pattern of the solid support, as described above.
  • a first compound 5 such as a poly(alkoxyglycothiol)
  • the printed solid support 6 is then contacted with a solution containing the peptide 2 under conditions suitable for reacting the peptide with the exposed solid support.
  • the thus formed SAM 7 possess a pattern of the peptide in the relief of the imprint of the first compound.
  • the SAM can then be washed and dried, as above.
  • the printed solid support 6 can be immersed into a solution of the peptide or the peptide can be poured or sprayed onto the surface of the SAM, as is convenient.
  • Solvents which can be used to ink the peptide onto the stamp and, then, onto the solid support include solvents which can disperse or, preferably, solubilize the peptide.
  • the solvent is preferably readily removed, for example, by evaporation, lyophilization or extraction, from the solid support.
  • preferred solvents include alcohols, such as ethanol, acetone, acetonitrile, DMSO and DMF and miscible combinations thereof.
  • the peptide solution concentration is selected such that the desired amount of peptide is delivered to the solid support. That is, if it is desired to print the peptide upon the solid support at a high concentration or density, then the peptide solution can be at or near the saturation level of a good solvent. If it is desired to imprint a low concentration of the peptide sparsely upon the solid support, the solution can be characterized by a low concentration such as employing a dilute solution.
  • the solution comprising the peptide can also include additional components.
  • a dispersant or solubilizer can be added to the solution to solubilize or disperse, for example, the peptide.
  • a colorant in the solution, particularly where the solution is colorless or is difficult to observe on the solid support or stamp, so that the area of the solid support which has been inked can be visually observed.
  • additional components are added to the solution that they can be readily removed from, e.g. washed free of, the solid support.
  • either the stamp, solid support or both can be mobile, relative to the other. That is, the stamp can be fixed and the solid support pressed firmly against it or vice versa. Alternatively, both the stamp and support can be mobilized. This process can be readily achieved employing robotics, which ensures a high degree of consistency and accuracy in the printing step.
  • the peptide can be bound to the solid support via covalent bonding, ionic bonding or other chemical interactions. It is preferred that the bonding be of a high affinity and be essentially irreversible under the conditions for use.
  • the conditions suitable for bonding the peptide to the solid support can be dependent upon the nature of the chemical reaction relied upon and can generally be determined by the person of skill employing no more than routine skill.
  • the SAMs of the invention can be employed in a variety of processes in biology, biotechnology, medicine, material science, biomedical engineering and computer-related inventions.
  • a preferred example of an application includes the use of the SAMs as substrates for ELISA.
  • the SAMs of the present invention can be used to screen for the presence of a target in a sample.
  • the SAMs of the invention can be designed to possess a presenting group which binds specifically or non-specifically to a target or target molecule.
  • the presenting group is “specific” to the target, i.e. does not bind substantially to other materials or cells which can be present.
  • the presenting group is non-specific to a particular target but can bind to a large number of targets.
  • the method of screening for the presence of a target can comprise the steps of contacting an SAM, as described above, with a sample under conditions suitable for the target or target molecule to bind to the presenting group on the SAM and detecting the presence of the target or target molecule.
  • the target or target molecule can be a cell, such as a mammalian cell (e.g., tumor cell, normal diploid somatic cell, or stem cell), a bacterium or yeast (e.g., a causative agent for disease or contaminant).
  • the target or target molecule can be a virus (e.g., a causative agent for disease or contaminant), toxin or protein, etc.
  • the sample can be obtained from an animal or patient, such as a tissue sample or biopsy, body fluid, e.g., serum, milk, saliva or urine or fecal matter.
  • the sample can be obtained from manufacturing process, such as a pharmaceutical process or food process.
  • the method can be used to screen for contaminants or sterile conditions in manufacturing or it can be used to screen for or diagnose disease in a patient.
  • the sample be contacted with the SAM as a liquid, e.g. a dispersion or solution.
  • the sample can be mixed with a diluent or buffer.
  • diluents include water, such as sterile water, polar and non-polar solvents, e.g. alcohols, dimethylformamide, acetonitrile, alkanes, benzene, toluene, etc.
  • Buffers include physiological buffers, such as phosphate buffered solution, culture media, etc.
  • the person of skill in the art can determine empirically the conditions for contacting the SAM and the sample such that the target or target molecule can react with each other and bind. Such conditions are well known in the art. Generally, where the method is a diagnostic tool and the sample is a tissue sample or other biological sample, the conditions will physiologic. That is, physiological pH is generally employed. Room temperature can also be employed in many instances. Where the method is detecting the presence of contaminants in a sample, neutral pH can be generally employed, as well as room temperature.
  • the SAM can be contacted with the sample in a number of ways.
  • the SAM can be immersed into the sample, as in dipping a stick.
  • the sample can be poured over or through the SAM.
  • the SAM can be rinsed after the contacting step, such as with sterile water.
  • the presence of the target or target molecule is detected.
  • the SAM can be contacted with a second solution which possesses a labeled compound which can react with the target molecule, as in an ELISA method.
  • the label e.g., a colorimetric label or radiolabel
  • the target can be detected visually, with the naked eye, under a microscope or robotically. This can be advantageous, for example, where the target is a cell. In many embodiments, it may be desirable to permit any cells bound to the SAM to colonize prior to detection.
  • the method of the invention can accurately determine the presence of an individual cell or determine a precise cell count in a sample.
  • the solid support for the SAM is transparent.
  • the presence of an opaque target, such as a cell can be determined by scanning the SAM with a laser and determining the number of targets or cells present thereon, which accurately correlates to the number of interruptions in scanning.
  • This method can be performed in an automated system (e.g. robotically), thereby improving efficiency and avoiding inaccurate results due to human error.
  • the SAMs of the invention can be used as a solid support in culturing cells.
  • Cells can be attached to the SAMs by contacting the cells to be attached with the SAM and maintaining the cells under conditions suitable for growth. As above, it is generally desirable to contact the cells with the SAM as a liquid, e.g., in the presence of a diluent or solvent.
  • the cells can be attached to the solid support in a predetermined fashion, order and orientation.
  • Conditions for maintaining cells can be those employed routinely for the cell or cell type to be cultures.
  • the culture can be maintained under temperatures (e.g. between about 25° C. to about 60° C.) and pH (e.g. between about 4 and about 10) appropriate for growth.
  • Nutrients appropriate for growth can also advantageously be provided to the culture.
  • the invention permits very accurate control of cell population and density.
  • the invention can be utilized to study cell growth and cellular interactions to external stimuli, including other cells, growth factors, repellants and inhibitors.
  • external stimuli including other cells, growth factors, repellants and inhibitors.
  • the invention represents a significant advance in the ability to conduct research in biology and medicine.
  • the method can be employed in screenings or assays employing cells, such as screening for drugs which may inhibit the growth of a cell or cells (such as in a screen for anti-tumor agents, anti-bacterials).
  • the method can be employed in the screening for drugs which increase or activate the growth of a cell or cells, including fibroblasts, endothelial cells, smooth muscle cells, hematopoietic cells and neuronal cells, etc.
  • the method can also be used to maintain cell cultures, including tissue cultures, in the manufacture of cellular products (e.g., proteins, hormones, etc.), artificial tissues, etc.
  • tissue cultures include fibroblasts, endothelial cells, smooth muscle cells and neuronal cells.
  • tissue can be employed as grafts, such as autologous grafts.
  • attractants e.g., growth factors, neuropeptides, neurotrophins, and drugs can be screened for their ability to alter the direction or growth behavior of neurites or their ability to induce, stimulate, suppress or inhibit neurite growth. These attractants can be placed or randomly contacted with the neuronal cell-bound SAMs.
  • Preferred peptides for the manufacture of the SAMs for this application include peptides wherein the presenting group is a cell adhesion motif or peptide which binds to neuronal cells.
  • suitable cell adhesion motifs are (RADX) n , (RADS) n , (EAKX) n , and (EAKS) n , wherein X is an amino acid, such as S, and n is an integer, preferably between about 2 to about 8. Oligopeptides of these sequences have been shown to promote neurite outgrowth in culture (U.S. application Ser. No. 08/784,606, which is incorporated herein by reference in its entirety).
  • a 10:1 (w:w) mixture of Sylgard Silicone Elastomer 184 and Sylgard Curing Agent 184 (Dow Corning Corp., Midland, Mich.) was casted over a master, which was generated by photolithography, and pressure degassed. After sitting at room temperature for 1 hour, the PDMS was cured at 60° C. for 2 hours. The stamp was carefully peeled off the master after cooling to room temperature and rinsed with ethanol. The PDMS stamp was inked by a cotton swab which has been moistened with a 5 mM solution of (1-mercaptoundec-11-yl)hexa(ethylene glycol) (HO(CH 2 CH 2 O) 6 (CH 2 ) 11 SH) in ethanol.
  • the resulting stamp was placed on the gold substrate (125 ⁇ gold on a titanium-primed 24 ⁇ 50-2 microscope cover glass) and gentle hand pressure was applied to aid in complete contact between the stamp and the glass chip. After 1 minute, the stamp was peeled off the glass chip and the resulting substrate was immersed directly in a 2 mM solution of (RADC) 3 AAAC (SEQ ID NO: 1) in distilled, deionized water. After approximately 2 hours of immesion, the glass chip was removed from the solution, rinsed extensively with water and ethanol, and dried with a stream of filtered nitrogen gas.
  • (RADC) 3 AAAC SEQ ID NO: 1

Abstract

This invention describes self assembled monolayers (SAMs) manufactured by imprinting reactive peptides onto solid supports. The invention further relates to methods of preparing and using these improved SAMs.

Description

    RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 10/071,500, filed Feb. 8, 2002 which is a continuation of U.S. application Ser. No. 08/882,415, filed Jun. 25, 1997. The entire teachings of the above application are incorporated herein by reference.[0001]
  • GOVERNMENT SUPPORT
  • [0002] The invention was supported, in whole or in part, by a grant (Grant No. 62874) from the Army Research Office. The Government has certain rights in the invention.
  • BACKGROUND OF THE INVENTION
  • Organic surfaces have been employed in numerous methods and systems, including as substrates for ELISA, cell and tissue culture. Self-assembled monolayers (SAMs) are a class of organic surfaces manufactured by imprinting a monolayer of organic compounds with reactive moieties onto a solid support under conditions wherein the compounds react with and bind to the solid support in a single ordered and patterned layer. See, Lopez, et al., “Convenient Methods for Patterning the Adhesion of Mammalian Cells to Surfaces Using Self-Assembled Monolayers of Alkanethiolates on Gold,” [0003] J. Am. Chem. Soc., 115(13):5877-5878 (1993) and Mrksich and Whitesides, “Using Self-Assembled Monolayers to Understand the Interactions of Man-Made Surfaces with Proteins and Cells”, Annu. Rev. Biophys. Biomol. Struct., 25:55-78 (1996). Molecular self-assembly is the spontaneous association of molecules under equilibrium conditions into stable, structurally well-defined order joined by non-covalent bonds. SAMs manufactured to date have linked chemical moieties to solid surfaces through long chain alkyl linkages. Examples of organic compounds which have been patterned on a solid support include alkanethiolates and alkylsiloxanes. The SAMs are manufactured employing a process termed “microcontact printing.”
  • It has been suggested that SAMs can be used to pattern cells on a surface by presenting chemical moieties which bind to the cells on the solid surface. Mrksich and Whitesides, above. However, these molecules, and the resulting SAMs, can be difficult and/or expensive to manufacture. Thus, improvements and cost reductions in the manufacture of SAMs are desirable and are necessary. [0004]
  • SUMMARY OF THE INVENTION
  • This invention is based upon the discovery that improved SAMs can be manufactured by imprinting reactive self assembling peptides onto solid supports. The SAMs are characterized by ease of manufacture and purification. They are versatile in their ability to readily provide a large variety of chemical reactive moieties, or “presenting groups”, to selected targets. For example, the SAM's of the present invention can be readily designed to present ligands to cellular receptors, cell adhesion motifs, antibodies or antigen-binding fragments thereof to cell surface proteins. This preferred class of SAMs can be used to bind a target, e.g. a selected cell or cells, to a predetermined locus on the solid support. [0005]
  • Thus, the invention relates to a composition of matter comprising a solid support and a self-assembled monolayer of linear peptides wherein said peptides bound directly to said solid support through a terminal amino acid in a predetermined pattern. Preferably, the peptides comprise a terminal reactive group, a central linker and a presenting group. The invention also relates to the uses and applications of the SAMs described herein, as will be described in more detail below. [0006]
  • The invention further relates to a method for manufacturing an SAM, or a composition of matter comprising a solid support and a self-assembled monolayer of linear peptides wherein said peptides bound directly to said solid support through a terminal amino acid in a predetermined pattern, comprising microcontact printing the reactive peptides onto the solid support and maintaining the peptides under conditions suitable for binding. [0007]
  • The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principals of the invention.[0008]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIGS. 1 and 2 illustrate methods of microcontact printing reactive peptides to a solid support in a predetermined pattern. [0009]
  • FIG. 3 illustrates patterns which may be selected, for example, in SAMs for immobilizing cells.[0010]
  • DETAILED DESCRIPTION OF THE INVENTION
  • As set forth above, the invention relates to improved SAMs comprising a predetermined pattern of peptides on a solid support. Preferred peptides of the invention can be characterized by three regions bound to each other through an amino acid or via peptide binding, the “terminal reactive group”, the “central linker” and the “presenting group.”[0011]
  • Upon binding the peptides to the solid support, the peptides are preferably highly ordered and preferably possess a consistent linear and parallel configuration with each other. Generally, the peptides, or the central linker thereof, are fully extended beta strands in configuration under the conditions of use. [0012]
  • Although in some embodiments, it may be desirable to present a ligand or other molecule which possesses a tertiary structure, generally, the peptides are linear (e.g., free or substantially free of branching or tertiary structure). “Substantially free” of branching or tertiary structure is intended to include minor amounts of branching and peptide interactions which do not significantly interfere with the free movement or function of the presenting group. The actual degree of branching and peptide interactions which can be tolerated without deleteriously effecting the quality of the product will be function of the overall length of the peptide, the branched peptides, the nature of the amino acids in each and their ability or tendency to interact with each other can generally be determined by routine screening or computer modeling. For example, peptides “substantially free” of branching may include a peptide composition wherein less than about 5% of the peptides are characterized by one or more branches. [0013]
  • While the length of the peptide is not critical to the invention, the peptide is preferably small to moderate in length. Thus, the central linker of the peptide can preferably be between about 2 to about 50 naturally occurring or non-naturally occurring amino acids in length are preferred, more preferably between about 8 to about 35 amino acids in length. Certain peptides in excess of [0014] 50 may present undesirable interactions of the peptides, such as a possible tendency of the peptide to fold. Peptide interactions can be predicted by, for example, computer modeling and structural information available at protein data banks at, for example, Brookhaven National Laboratories, N.Y.
  • Peptides which can be used in the invention can be characterized by a reactive moiety which can react and bind to the solid support, the “terminal reactive group”. Typically, the terminal reactive group is an amino acid characterized by a functional group pendant from the side chain, the amino group or the carboxy group. Thus, the terminal reactive group which binds to the solid support can be an amino acid substituted by a hydroxy, thiol, carboxy, amino, amido, imido or guanidino group. Preferred terminal amino acids, thus, include serine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine and histidine. Alternatively, the terminal reactive group can be a normaturally-occurring amino acid characterized by a functionality which can react with the solid support. Examples include beta amino acids (amino acids wherein the amino and/or carboxy group are not substituted on the same alpha carbon, such as beta-alanine) or amino acids which have been chemically modified, by electrophilic substitution, nucleophilic substitution, activation reactions or addition reactions, for example. See March, “Advanced Chemistry,” Third Edition (1985), Chapters 10-16, the contents of which are incorporated herein by reference. [0015]
  • It is further desirable that the peptide be of sufficient length to provide a flexible, spatial separation between the solid support (upon reaction with the reactive terminal group) and the opposing reactive terminus of the peptide (e.g., the presenting group). Thus, the peptides of the invention preferably comprise a “central linker”, which is a peptide bound to the terminal reactive group and presenting group through peptide or amide bonds. The amino acids employed in the peptide and/or central linker are selected to promote or optimize a beta strand configuration at the conditions for use. It is further preferred that the amino acids in this portion of the peptide be substantially free of large or bulky side chains or bonds which will interfere with the configuration (e.g. proline). The amino acids can further be selected considering material strength, permeability and degradation rate of the resulting peptide and SAM. Preferably, the amino acids selected for the central section of the peptide are glycine, L-alanine and D-alanine. D-amino acids have advantages in many applications due to their resistance to L-protease degradation. [0016]
  • The length of the central linker where present, is also generally not critical to the invention. Preferably, the central linker is between about 2 and about 30 amino acids in length, more preferably between about 2 and about 8 amino acids. [0017]
  • The peptide can also be characterized by a “presenting moiety” which will bind to one or more targets. The term “presenting group” is defined herein to include one or more chemical atoms, functional groups, amino acids or peptides that possess an affinity to or resistance for a target entity. For example, a presenting group which presents a resistance for a target entity, e.g., a protein or cell, can be poly(ethylene glycol) or another compound which is inert to the target. A presenting group which is resistant to water, as a target molecule, is a hydrophobic group, such as a high chain alkyl or hydrophobically blocked amino acid (e.g., an alkyl ester of valine, leucine, isoleucine or phenylalanine). [0018]
  • Generally, one or more peptides employed in the present invention possess a presenting group with an affinity for a target, e.g. a target molecule. In such embodiments, the presenting group can be specific or non-specific for the target molecule. For example, where the target is a cell, the target molecule can be a cell surface protein. The presenting group can be a ligand for that protein, an antibody or an antigen-binding fragment thereof which binds specifically to the cell surface protein. [0019]
  • The presenting group can be a non-peptide or, preferably, a peptide. As discussed above, the presenting group can be a ligand for or an antibody or antibody fragment which binds to the target molecule. [0020]
  • Particularly suitable presenting groups are oligopeptides which self assemble to form a beta sheet under conditions for the desired or selected application. Examples of oligopeptides which self assemble under these conditions are described in U.S. application Ser. Nos. 08/346,849 and 08/784,606, which are incorporated herein by reference in their entireties. Briefly, these oligopeptides are amphiphilic, have alternating hydrophobic and hydrophilic amino acids and are complementary. As will be described in more detail below, particularly preferred oligopeptides for self assembly are RADX[0021] n and EAKXn wherein X is an amino acid and n is an integer between about 2 and about 8.
  • Particularly preferred targets include cells. Examples of cells which can be targeted include prokaryotic and eukaryotic cells. The cells can be mammalian, plant, bacterial, and yeast. Mammalian cells which can be targeted include tumor cells, normal somatic cells and stem cells. The cells can be fibroblasts, endothelial cells, neuronal cells, hepatocytes, blood cells, smooth muscle cells, and progenitors thereof, for example. Bacterial cells can be gram positive or gram negative bacteria and can include [0022] Escherichia coli, Streptococcus, Staphylococcus, as well as many others. Bacterial cells which may be desirable to target and, thus detect and/or culture, can include pathogens and non-pathogens, e.g., contaminants in a food sample, a mammalian tissue sample or serum sample or in a plant tissue sample. Similarly, yeast can be targeted and include, for example, Candida and Saccharomyces.
  • Cells can preferably be targeted by selecting a presenting group which will react with and bind to the cell surface. Generally, this is accomplished by binding to a cell surface molecule, such as a protein, lipid, or sugar at the surface of the protein. These surface molecules are included herein as “target molecules.” For example, a target molecule can be a cell surface protein and can be specific to the target or, in this case, cell, or the target molecule can be non-specific. Where the object of the application is to detect the presence of a cell in a sample, e.g., a tumor cell in a sample which can contain normal cells, it is desirable that the target molecule be specific to the tumor cell (e.g., present on tumor cells and absent on the normal cells). These molecules are generally known in the art as tumor markers. Where the object of the invention is to detect the presence of bacteria in a sample, such as in food, tissue sample, blood sample, or pharmaceutical, it can be desirable to select a target molecule which is present on many types of bacteria which are potentially contaminating the sample to be tested. In other instances, e.g., where a substantially pure cell culture is being targeted or transferred to the solid support, the selection of specific or non-specific target molecule is immaterial. [0023]
  • Suitable target molecules include tumor markers, cellular receptors, such as CD4 and, CD8. Neuronal cellular receptors include N-CAMs, the L1 receptors, NGF receptor, the netrin receptor and others. [0024]
  • Targets can include non-cellular products as well, including viruses (such as retroviruses, influenza viruses, and herpesviruses, for example), and proteins (such as prostate soluble antigen (PSA), cytokines, cytokine receptors, growth factors, and growth factor recpetors. Where the target is a virus, the target molecule can be a surface protein as well, such as a cellular receptor implicated in the infection of cells. A particularly preferred target molecule for HIV is, for example, gp120. [0025]
  • Examples of presenting groups include cellular adhesion motifs, ligands or binding fragments of ligands for the target molecule (e.g., the ligand for gp120 is CD4), antibodies or antigen binding fragments of antibodies which bind to the target molecule. [0026]
  • A ligand is defined here to include molecules which are the same as or substantially the same as the native molecule which binds the target molecule. For example, CD4 is a native ligand for the HIV env protein, gp120. Thus, where the target molecule is gp120, the term “ligand” and, thus, the presenting groups include native CD4, a ligand-binding fragment of CD4 (such as, an extracellular domain), and mutations thereof which bind to gp120. [0027]
  • The terminal reactive group, central linker and presenting group are preferably arranged linearly with the central linker bonded directly or indirectly to both the reactive group and the presenting group through, e.g., peptide bonds. Preferably, the peptide has the formula: [0028]
  • X—(CH2)n—CH(NH2)CO(AA)m-L
  • or [0029]
  • X—(CH2)n—CH(COOH)NH(AA)m-L
  • wherein X is an inert group, such as H, alkyl, alkoxy, alkylthio or dialkylamine, or is a labile or reactive group, such as a thiol, hydroxy, amino, carboxy, acylhalide, carboxy ester, or halide; [0030]
  • AA is, independently, the same or different, naturally-occurring or non-naturally-occurring amino acid, and is preferably, glycine, L-alanine or D-alanine; [0031]
  • L is a group which binds specifically or non-specifically to a target and is preferably a peptide, such as a ligand, an antibody or an antibody fragment; [0032]
  • n is zero or an integer between 1 to about 5; [0033]
  • m is an integer of at least about 2 and, preferably, between about 2 and about 50, more preferably between about 2 and about 8. [0034]
  • The peptides of the invention can be manufactured by known and industry stadnard peptide synthesis technology. For example, the peptides can be synthesized chemically or recombinantly (e.g. by the expression of a recombinant nucleic acid molecule which encodes the peptide or a precursor thereof). A precursor of the peptide can be particularly beneficial where one or more of the amino acids are non-naturally occurring (e.g. a beta amino acid or an amino acid with a non-naturally occurring side chain). The manufacture of peptides chemically and recombinantly are generally practiced in the art and are described in, for example, U.S. application Ser. Nos. 08/346,849 and 08/784,606 and Ausubel, [0035] Current Protocols in Molecular Biology (1997). The peptides can preferably be purified prior to use in the manufacture of the SAMs by standard techniques, including HPLC.
  • The peptides employed in the invention are imprinted or patterned on a solid support. The shape of the solid support is not critical to the invention and can be selected to optimize ease of use in the particular application. Thus, the solid support can be substantially spherical (e.g., a bead) or non-spherical, such as in a container (e.g., a petri dish or cup), cylinder or cone, or a substantially flat film, stick, chip or disc, of essentially any size suitable for the ultimate application. The solid support can be porous (as in a membrane) or non-porous (as in a petri dish or container). [0036]
  • The material employed in the manufacture of the solid support is not critical as well. Thus, a variety of materials can be employed in the manufacture of the solid support. For example, the solid support can be an inorganic material such as a metal, including as gold, copper, zinc, silver or nickel or a metal alloy. Alternatively, the solid support can be glass, silica, or silicon oxide. In yet another embodiment, the solid support can be an organic material, such as a polymer or resin, including nylon, poly(ethylene glycol), and polyfluoropolymers. It can be desirable in some embodiments to employ a transparent solid support. In this embodiment, the detection of the binding of an opaque target (e.g., a cell) can be determined readily and accurately visually or electronically and/or robotically employing, for example, a laser under the control of a computer. [0037]
  • The solid support is selected with a view towards its ability to react with the terminal reactive group of the peptide. For example, the thiol group (e.g., X) can react with gold under standard methods, as described, for example in Mrkisch and Whitesides, above. Likewise, the hydroxy group (e.g., X) can react with siloxane under relatively mild conditions. Xia, et al. “Microcontact Printing of Octadecylsiloxane on the Surface of Silicon Dioxide and Its Application in Microfabrication,” [0038] J. Am. Chem. Soc. 117:9576-9577 (1995).
  • Solid supports which are inert to the peptide can be derivatized to render them reactive. For example, the solid support can be coated with a reactive material, chemically treated (e.g., by electrophilic or nucleophilic substitution reaction, addition reactions, etc.) to introduce reactive groups. [0039]
  • The peptides are printed on the solid support, as will be described below. The terms “printed”, “patterned” or “predetermined pattern” are defined herein to mean that the solid support has ordered areas where the peptides are bonded and not bonded to the solid support. That is, a printed or patterned solid support is expressly not intended to include a support with random or substantially homogeneous distribution of the peptide over its entire surface(s). Furthermore, the peptides are printed on the solid support in a single layer in a substantially consistent configuration. Thus, the terms are further not intended to include solid supports wherein peptides are bonded to the solid support via distinct and different functional groups across the same molecule (e.g., distinct cysteine residues in a protein containing multiple cysteines along its sequence). [0040]
  • The patterns which can be selected in this invention are not particularly critical. Preferred patterns for SAMs useful as research tools in the study of cell/cell interactions are linear tracks of alternating peptides which can adhere to the cells and inert tracks of solid support or an inert compound bound to the solid support. Depending upon the thickness of the tracks, the orientation of the cell can further be manipulated. That is a thin track can result in the orientation of the cells linearly. FIG. 3 exemplifies suitable patterns. [0041]
  • As stated above, methods for the manufacture of SAMs are generally known in the art. U.S. Pat. Nos. 5,620,850 and 5,512,131 and PCT Published Application Nos.: W097/07429 and W096/29629 decribed suitable methods for manufacture. Additional examples include Deng, Li, Milan Mrksich and George M. Whitesides, “Self-Assembled Monolayers of Alkanethiolates Presenting Tri(propylene sulfoxide) Groups Resist the Adsorption of Protein,” [0042] J. Am. Chem. Soc., 118(21):5136-5137 (1996); Chen, Christopher S., Milan Mrksich, Sui Huang, George M. Whitesides, Donald E. Ingber, “Geometric Control of Cell Life and Death,” Science, 276:1425-1428 (1997); López, Gabriel P., Mark W. Albers, Stuart L. Schreiber, Reed Carroll, Ernest Peralta, and George M. Whitesides, “Convenient Methods for Patterning the Adhesion of Mammalian Cells to Surfaces Using Self-Assembled Monolayers of Alkanethiolates on Gold,” J. Am. Chem. Soc., 115(13):5877-5878 (1993); Kumar, Amit, Nicholas L. Abbott, Enoch Kim, Hans A. Biebuyck, and George M. Whitesides, “Patterned Self-Assembled Monolayers and Meso-Scale Phenomena,” Acc. Chem. Res., 28(5):219-226 (1995); DiMilla, Paul A., John P. Folkers, Hans A. Biebuyck, Ralph Harter, Gabriel P. López, and George M. Whitesides, “Wetting and Protein Adsorption of Self-Assembled Monolayers of Alkanethiolates Supported on Transparent Films of Gold,” J. Am. Chem. Soc., 116(5):2225-2226 (1994); Singhvi, Rahul, Amit Kumar, Gabriel P. Lopez, Gregory N. Stephanopoulos, Daniel I. C. Wang, George M. Whitesides, Donald E. Ingber, “Engineering Cell Shape and Function,” Science, 264:696-698 (1994); Mrksich, Milan and George M. Whitesides, “Using Self-Assembled Monolayers to Understand the Interactions of Man-Made Surfaces with Proteins and Cells,” Annu. Rev. Biophys. Biomol. Struct., 25:55-78 (1996); Wilbur, James L., Amit Kumar, Enoch Kim, George M. Whitesides, “Microfabrication by Microcontact Printing of Self-Assembled Monolayers,” Adv. Mater. 6(7/8):600-604 (1994); Xia, Younan, Enoch Kim, Milan Mrksich and George M. Whitesides, “Microcontact Printing of Alkanethiols on Copper and Its Application in Microfabrication,” Chem. Mater. 8(3):601-603 (1996); Mrksich, Milan, Jocelyn R. Grunwell and George M. Whitesides, “Biospecific Adsorption of Carbonic Anhydrase to Self-Assembled Monolayers of Alkanethiolates that Present Benzenesulfonamide Groups on Gold,” J. Am. Chem. Soc., 117(48):12009-12010 (1995); Jeon, Noo Li, Ralph G. Nuzzo, Younan Xia, Milan Mrksich, and George M. Whitesides, “Patterned Self-Assembled Monolayers Formed by Microcontact Printing Direct Selective Metalization by Chemical Vapor Deposition on Planar and Nonplanar Substrates,” Langmuir, 11(8):3024-3026 (1995); Xia, Younan, Milan Mrksich, Enoch Kim and George M. Whitesides, “Microcontact Printing of Octadecylsiloxane on the Surface of Silicon Dioxide and Its Application in Microfabrication,” J. Am. Chem. Soc., 117(37):9576-9577 (1995). The contents of these articles are incorporated herein by reference. The method is illustrated in FIGS. 1 and 2.
  • Referring specifically to FIG. 1, a polymeric or elastomeric stamp [0043] 1 (e.g. a polydimethylsiloxane stamp) is contacted or “inked” with a solution 2 containing the peptide in a suitable solvent and then the inked stamp is pressed against the solid support 3, thereby transferring the peptide solution in a controlled fashion to the solid support 3. The peptide is then maintained in contact with the solid support 3 under conditions suitable for binding, resulting in a SAM 4.
  • Upon binding of the peptide to the solid support, the solvent is generally removed, for example, by washing (e.g., extraction), evaporation or lyophilization. [0044]
  • The patterned SAM thus formed can then be used directly or can be further derivatized, e.g., by subjecting the SAM to a second printing step to ink a different chemical compound thereon. The second chemical compound can preferably be a peptide of the claimed invention or can be different, such as an alkanethiol or poly(ethylene glycol), as described in Mrksich and Whitesides, above. [0045]
  • In yet another alternative, the SAM can be subjected to additional steps which can modify the peptide on the SAM. This embodiment may be desirable where the presenting group (e.g., L) or the chemical bond to the central linker ((AA)[0046] m) is labile under the conditions for binding the peptide to the solid support. Thus, the presenting group can be chemically reacted with a peptide precursor bonded directly to the solid support, thereby obtaining a SAM of the present invention.
  • In many instances, it can be desirable to modify the exposed areas of the solid support, for example, by exposing the SAM to ultraviolet light or oxidize the SAM. This can be done to improve the reactivity or eliminate reactivity of the material of the solid support with one or more materials encountered in storage or in use of the SAM. [0047]
  • Referring to FIG. 2, the [0048] solid support 3 is stamped with a solution containing a first compound 5 (such as a poly(alkoxyglycothiol)) which can react with the solid support and presents an imprint or pattern of the solid support, as described above. The printed solid support 6 is then contacted with a solution containing the peptide 2 under conditions suitable for reacting the peptide with the exposed solid support. The thus formed SAM 7 possess a pattern of the peptide in the relief of the imprint of the first compound. The SAM can then be washed and dried, as above. The printed solid support 6 can be immersed into a solution of the peptide or the peptide can be poured or sprayed onto the surface of the SAM, as is convenient.
  • Solvents which can be used to ink the peptide onto the stamp and, then, onto the solid support include solvents which can disperse or, preferably, solubilize the peptide. The solvent is preferably readily removed, for example, by evaporation, lyophilization or extraction, from the solid support. Examples of preferred solvents include alcohols, such as ethanol, acetone, acetonitrile, DMSO and DMF and miscible combinations thereof. The peptide solution concentration is selected such that the desired amount of peptide is delivered to the solid support. That is, if it is desired to print the peptide upon the solid support at a high concentration or density, then the peptide solution can be at or near the saturation level of a good solvent. If it is desired to imprint a low concentration of the peptide sparsely upon the solid support, the solution can be characterized by a low concentration such as employing a dilute solution. [0049]
  • The solution comprising the peptide can also include additional components. For example, a dispersant or solubilizer can be added to the solution to solubilize or disperse, for example, the peptide. It can be desirable in some instances to include a colorant in the solution, particularly where the solution is colorless or is difficult to observe on the solid support or stamp, so that the area of the solid support which has been inked can be visually observed. It is generally desirable where additional components are added to the solution that they can be readily removed from, e.g. washed free of, the solid support. [0050]
  • It is clear that, in the method for manufacturing the SAMs, either the stamp, solid support or both can be mobile, relative to the other. That is, the stamp can be fixed and the solid support pressed firmly against it or vice versa. Alternatively, both the stamp and support can be mobilized. This process can be readily achieved employing robotics, which ensures a high degree of consistency and accuracy in the printing step. [0051]
  • The peptide can be bound to the solid support via covalent bonding, ionic bonding or other chemical interactions. It is preferred that the bonding be of a high affinity and be essentially irreversible under the conditions for use. The conditions suitable for bonding the peptide to the solid support can be dependent upon the nature of the chemical reaction relied upon and can generally be determined by the person of skill employing no more than routine skill. [0052]
  • Clearly, other methods for the manufacture of the SAMs of the present invention will be apparent to the person of skill in the art and are intended to be included within the scope of the present invention. [0053]
  • The SAMs of the invention can be employed in a variety of processes in biology, biotechnology, medicine, material science, biomedical engineering and computer-related inventions. A preferred example of an application includes the use of the SAMs as substrates for ELISA. [0054]
  • SAMs to Screen for the Presence of a Target in a Sample [0055]
  • The SAMs of the present invention can be used to screen for the presence of a target in a sample. As set forth above, the SAMs of the invention can be designed to possess a presenting group which binds specifically or non-specifically to a target or target molecule. Where the presence of a cell is to be detected and distinguished from other cells in the sample (e.g., the presence of a tumor cell in a tissue sample which can further comprise normal diploid cells), the presenting group is “specific” to the target, i.e. does not bind substantially to other materials or cells which can be present. Where the presence of many different cells in a sample (e.g., the presence of bacterial contaminants in a pharmaceutical process stream), the presenting group is non-specific to a particular target but can bind to a large number of targets. [0056]
  • The method of screening for the presence of a target can comprise the steps of contacting an SAM, as described above, with a sample under conditions suitable for the target or target molecule to bind to the presenting group on the SAM and detecting the presence of the target or target molecule. The target or target molecule can be a cell, such as a mammalian cell (e.g., tumor cell, normal diploid somatic cell, or stem cell), a bacterium or yeast (e.g., a causative agent for disease or contaminant). Alternatively, the target or target molecule can be a virus (e.g., a causative agent for disease or contaminant), toxin or protein, etc. [0057]
  • The sample can be obtained from an animal or patient, such as a tissue sample or biopsy, body fluid, e.g., serum, milk, saliva or urine or fecal matter. Alternatively, the sample can be obtained from manufacturing process, such as a pharmaceutical process or food process. Thus, the method can be used to screen for contaminants or sterile conditions in manufacturing or it can be used to screen for or diagnose disease in a patient. [0058]
  • It is generally desirable that the sample be contacted with the SAM as a liquid, e.g. a dispersion or solution. Thus, the sample can be mixed with a diluent or buffer. Examples of diluents include water, such as sterile water, polar and non-polar solvents, e.g. alcohols, dimethylformamide, acetonitrile, alkanes, benzene, toluene, etc. Buffers include physiological buffers, such as phosphate buffered solution, culture media, etc. [0059]
  • The person of skill in the art can determine empirically the conditions for contacting the SAM and the sample such that the target or target molecule can react with each other and bind. Such conditions are well known in the art. Generally, where the method is a diagnostic tool and the sample is a tissue sample or other biological sample, the conditions will physiologic. That is, physiological pH is generally employed. Room temperature can also be employed in many instances. Where the method is detecting the presence of contaminants in a sample, neutral pH can be generally employed, as well as room temperature. [0060]
  • The SAM can be contacted with the sample in a number of ways. For example, the SAM can be immersed into the sample, as in dipping a stick. Alternatively, the sample can be poured over or through the SAM. Optionally, the SAM can be rinsed after the contacting step, such as with sterile water. [0061]
  • After the SAM has been contacted with the sample, the presence of the target or target molecule is detected. This can also be performed in a number of ways. In one embodiment, the SAM can be contacted with a second solution which possesses a labeled compound which can react with the target molecule, as in an ELISA method. The label (e.g., a colorimetric label or radiolabel) can then be detected. In many embodiments, the target can be detected visually, with the naked eye, under a microscope or robotically. This can be advantageous, for example, where the target is a cell. In many embodiments, it may be desirable to permit any cells bound to the SAM to colonize prior to detection. The method of the invention can accurately determine the presence of an individual cell or determine a precise cell count in a sample. [0062]
  • In a particularly preferred method, the solid support for the SAM is transparent. In such an embodiment, the presence of an opaque target, such as a cell, can be determined by scanning the SAM with a laser and determining the number of targets or cells present thereon, which accurately correlates to the number of interruptions in scanning. This method can be performed in an automated system (e.g. robotically), thereby improving efficiency and avoiding inaccurate results due to human error. [0063]
  • SAMS in Cell Culture [0064]
  • The SAMs of the invention can be used as a solid support in culturing cells. Cells can be attached to the SAMs by contacting the cells to be attached with the SAM and maintaining the cells under conditions suitable for growth. As above, it is generally desirable to contact the cells with the SAM as a liquid, e.g., in the presence of a diluent or solvent. The cells can be attached to the solid support in a predetermined fashion, order and orientation. [0065]
  • Conditions for maintaining cells can be those employed routinely for the cell or cell type to be cultures. For example, the culture can be maintained under temperatures (e.g. between about 25° C. to about 60° C.) and pH (e.g. between about 4 and about 10) appropriate for growth. Nutrients appropriate for growth can also advantageously be provided to the culture. [0066]
  • The invention permits very accurate control of cell population and density. The invention can be utilized to study cell growth and cellular interactions to external stimuli, including other cells, growth factors, repellants and inhibitors. Thus, the invention represents a significant advance in the ability to conduct research in biology and medicine. [0067]
  • In yet another embodiment, the method can be employed in screenings or assays employing cells, such as screening for drugs which may inhibit the growth of a cell or cells (such as in a screen for anti-tumor agents, anti-bacterials). Alternatively, the method can be employed in the screening for drugs which increase or activate the growth of a cell or cells, including fibroblasts, endothelial cells, smooth muscle cells, hematopoietic cells and neuronal cells, etc. [0068]
  • The method can also be used to maintain cell cultures, including tissue cultures, in the manufacture of cellular products (e.g., proteins, hormones, etc.), artificial tissues, etc. Examples of tissues which can be cultured in this manner include fibroblasts, endothelial cells, smooth muscle cells and neuronal cells. Such tissues can be employed as grafts, such as autologous grafts. [0069]
  • The understanding of complex neuronal connections is central to our comprehension of central nervous system function, and advances in doing so will benefit from combining engineering with molecular cell biology to analyze neuronal behavior under well-characterized and controlled conditions. Neurite outgrowth, guidance and connections can be studied on surfaces patterned with self-assembling peptides that contain cell-adhesion motifs. Controlling neurite outgrowth, including distances, angles and direction, can be important in controlling and studying synapse formation between neuronal cells guided into proximity. Neuronal cells attached to the described SAMs can be employed in the study of neuronal cell culture, synapse formation, neuronal connection engineering, screening neuropeptides, as well as pharmaceutical agents that stimulate, inhibit or alter the nature of nerve growth, and inter-connections. For example, attractants, e.g., growth factors, neuropeptides, neurotrophins, and drugs can be screened for their ability to alter the direction or growth behavior of neurites or their ability to induce, stimulate, suppress or inhibit neurite growth. These attractants can be placed or randomly contacted with the neuronal cell-bound SAMs. [0070]
  • Preferred peptides for the manufacture of the SAMs for this application include peptides wherein the presenting group is a cell adhesion motif or peptide which binds to neuronal cells. Examples of suitable cell adhesion motifs are (RADX)[0071] n, (RADS)n, (EAKX)n, and (EAKS)n, wherein X is an amino acid, such as S, and n is an integer, preferably between about 2 to about 8. Oligopeptides of these sequences have been shown to promote neurite outgrowth in culture (U.S. application Ser. No. 08/784,606, which is incorporated herein by reference in its entirety).
  • EXAMPLE 1
  • Preparation of Patterned SAMs Glass Chip [0072]
  • A 10:1 (w:w) mixture of Sylgard Silicone Elastomer 184 and Sylgard Curing Agent 184 (Dow Corning Corp., Midland, Mich.) was casted over a master, which was generated by photolithography, and pressure degassed. After sitting at room temperature for 1 hour, the PDMS was cured at 60° C. for 2 hours. The stamp was carefully peeled off the master after cooling to room temperature and rinsed with ethanol. The PDMS stamp was inked by a cotton swab which has been moistened with a 5 mM solution of (1-mercaptoundec-11-yl)hexa(ethylene glycol) (HO(CH[0073] 2CH2O)6(CH2)11SH) in ethanol. The resulting stamp was placed on the gold substrate (125 Å gold on a titanium-primed 24×50-2 microscope cover glass) and gentle hand pressure was applied to aid in complete contact between the stamp and the glass chip. After 1 minute, the stamp was peeled off the glass chip and the resulting substrate was immersed directly in a 2 mM solution of (RADC)3 AAAC (SEQ ID NO: 1) in distilled, deionized water. After approximately 2 hours of immesion, the glass chip was removed from the solution, rinsed extensively with water and ethanol, and dried with a stream of filtered nitrogen gas.
  • In our preliminary experiments, when the cells (of various types) are plated on surfaces coated with hexa-ethyleneglycolthiol, (EG)6-SH, they rarely attach to the surface. In contast, cells attached very well when plated on the surface coated with the “RADSC” peptide. In these experiments, after cell attachment, the plates containing cells wee shacked at 150 rpm for 10 minutes and the coated cover-slides were washed in new medium and transferred to new plates in order to eliminate unattached cells. [0074]
  • While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims. [0075]

Claims (7)

What is claimed is:
1. A device comprising:
a solid support; and
an array of isolated regions on the support, the array comprising a layer of peptides, wherein the peptides are bound to the support by a bond between the support and a terminal amino acid in a preselected, reproducible pattern.
2. The device of claim 1 further comprising a background region surrounding the isolated regions, wherein the peptides are not bound to the background region.
3. The device of claim 2 wherein the background region comprises an inert compound.
4. A device comprising:
a solid support; and
an isolated region comprising a layer of peptides, wherein the peptides are bound to the support by a bond between the support and a terminal reactive group in a preselected, reproducible pattern.
5. The device of claim 4 comprising a plurality of isolated regions of a self-assembled monolayer, the plurality of regions defining an ordered array on the support.
6. A device comprising:
a solid support;
an isolated region comprising a self-assembled monolayer of peptides, wherein the peptides are bound to the support by a bond between the support and a terminal reactive group in a preselected, reproducible pattern; and
a background region surrounding the isolated region and comprising a compound which can react with the support.
7. A device for immobilizing at least one biological material in a specific and predetermined pattern comprising:
a surface,
an array of immobilization islands in a specific and predetermined pattern over the surface isolated from each other by at least one background region, the array of immobilization islands comprising a first self-assembled monolayer comprising at least one first functional group wherein the at least one first functional group is selected to biophilic, and wherein the first self-assembled monolayer comprises a monolayer of linear peptides, the at least one background region comprising a second self-assembled monolayer having a second functional group wherein the second functional group is selected to be biophobic.
US10/317,838 1997-06-25 2002-12-11 Self-assembling peptide surfaces for cell patterning and interactions Abandoned US20040023414A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/317,838 US20040023414A1 (en) 1997-06-25 2002-12-11 Self-assembling peptide surfaces for cell patterning and interactions
US11/068,936 US20060019309A1 (en) 1997-06-25 2005-02-28 Self-assembling peptide surfaces for cell patterning and interactions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/882,415 US6368877B1 (en) 1997-06-25 1997-06-25 Self-assembling peptide surfaces for cell patterning and interactions
US10/071,500 US20020072074A1 (en) 1997-06-25 2002-02-08 Self-assembling peptide surfaces for cell patterning and interactions
US10/317,838 US20040023414A1 (en) 1997-06-25 2002-12-11 Self-assembling peptide surfaces for cell patterning and interactions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/071,500 Continuation US20020072074A1 (en) 1997-06-25 2002-02-08 Self-assembling peptide surfaces for cell patterning and interactions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/068,936 Continuation US20060019309A1 (en) 1997-06-25 2005-02-28 Self-assembling peptide surfaces for cell patterning and interactions

Publications (1)

Publication Number Publication Date
US20040023414A1 true US20040023414A1 (en) 2004-02-05

Family

ID=25380530

Family Applications (4)

Application Number Title Priority Date Filing Date
US08/882,415 Expired - Lifetime US6368877B1 (en) 1997-06-25 1997-06-25 Self-assembling peptide surfaces for cell patterning and interactions
US10/071,500 Abandoned US20020072074A1 (en) 1997-06-25 2002-02-08 Self-assembling peptide surfaces for cell patterning and interactions
US10/317,838 Abandoned US20040023414A1 (en) 1997-06-25 2002-12-11 Self-assembling peptide surfaces for cell patterning and interactions
US11/068,936 Abandoned US20060019309A1 (en) 1997-06-25 2005-02-28 Self-assembling peptide surfaces for cell patterning and interactions

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US08/882,415 Expired - Lifetime US6368877B1 (en) 1997-06-25 1997-06-25 Self-assembling peptide surfaces for cell patterning and interactions
US10/071,500 Abandoned US20020072074A1 (en) 1997-06-25 2002-02-08 Self-assembling peptide surfaces for cell patterning and interactions

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/068,936 Abandoned US20060019309A1 (en) 1997-06-25 2005-02-28 Self-assembling peptide surfaces for cell patterning and interactions

Country Status (2)

Country Link
US (4) US6368877B1 (en)
WO (1) WO1998058967A1 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020094572A1 (en) * 1993-10-04 2002-07-18 Rahul Singhvi Method of formation of microstamped patterns of plates for adhesion of cells and other biological materials, devices and uses therefor
US20060202943A1 (en) * 2005-03-11 2006-09-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Self assembly of elements for displays
US20060202944A1 (en) * 2005-03-11 2006-09-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Elements for self assembling displays
US20060220988A1 (en) * 2005-04-04 2006-10-05 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Self assembling display with substrate
US20060220989A1 (en) * 2005-04-04 2006-10-05 Hillis W D Method of assembling displays on substrates
US20060238464A1 (en) * 2005-04-22 2006-10-26 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Superimposed displays
US20070030220A1 (en) * 2005-03-11 2007-02-08 Searete Llc Self assembling display with substrate
US20070203062A1 (en) * 2005-04-25 2007-08-30 Rutledge Ellis-Behnke Compositions and methods for promoting hemostasis and other physiological activities
US20080032425A1 (en) * 2006-08-03 2008-02-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method of assembling displays on substrates
US20080032934A1 (en) * 2005-04-25 2008-02-07 Clear Nano Solutions Compositions for prevention of adhesions and other barrier applications
US20080091233A1 (en) * 2006-04-25 2008-04-17 Massachusetts Institute Of Technology Compositions and methods for affecting movement of contaminants, bodily fluids or other entities, and/or affecting other physiological conditions
US20080133641A1 (en) * 2005-08-01 2008-06-05 Gent Robert Paul Van Methods for publishing content
US20080274979A1 (en) * 2007-03-14 2008-11-06 Rutledge Ellis-Behnke Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
US20100019991A1 (en) * 2005-03-11 2010-01-28 Searete Llc Superimposed displays
US20100065188A1 (en) * 2005-03-11 2010-03-18 Searete Llc Self assembly of elements for displays
US20100128069A1 (en) * 2005-03-11 2010-05-27 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method of assembling displays on substrates
US20110236261A1 (en) * 2008-12-11 2011-09-29 Koninklijke Philips Electronics N.V. Sensing device for detecting target elements in a fluid
US9339476B2 (en) 2013-08-22 2016-05-17 Arch Biosurgery, Inc. Implantable meshes for controlling the movement of fluids
US9439941B2 (en) 2009-12-14 2016-09-13 The University Of Hong Kong Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6776094B1 (en) * 1993-10-04 2004-08-17 President & Fellows Of Harvard College Kit For Microcontact Printing
AU6774996A (en) * 1995-08-18 1997-03-12 President And Fellows Of Harvard College Self-assembled monolayer directed patterning of surfaces
US6368877B1 (en) * 1997-06-25 2002-04-09 Massachusetts Institute Of Technology Self-assembling peptide surfaces for cell patterning and interactions
US7163712B2 (en) * 2000-03-03 2007-01-16 Duke University Microstamping activated polymer surfaces
US6444254B1 (en) * 2000-03-03 2002-09-03 Duke University Microstamping activated polymer surfaces
US6770721B1 (en) 2000-11-02 2004-08-03 Surface Logix, Inc. Polymer gel contact masks and methods and molds for making same
US7033821B2 (en) * 2000-11-08 2006-04-25 Surface Logix, Inc. Device for monitoring cell motility in real-time
US7326563B2 (en) 2000-11-08 2008-02-05 Surface Logix, Inc. Device and method for monitoring leukocyte migration
US6893851B2 (en) 2000-11-08 2005-05-17 Surface Logix, Inc. Method for arraying biomolecules and for monitoring cell motility in real-time
US6864065B2 (en) * 2000-11-08 2005-03-08 Surface Logix, Inc. Assays for monitoring cell motility in real-time
US6844184B2 (en) * 2000-11-08 2005-01-18 Surface Logix, Inc. Device for arraying biomolecules and for monitoring cell motility in real-time
US7374906B2 (en) 2000-11-08 2008-05-20 Surface Logix, Inc. Biological assays using gradients formed in microfluidic systems
US6699665B1 (en) * 2000-11-08 2004-03-02 Surface Logix, Inc. Multiple array system for integrating bioarrays
US7033819B2 (en) 2000-11-08 2006-04-25 Surface Logix, Inc. System for monitoring cell motility in real-time
JP5057629B2 (en) * 2001-02-06 2012-10-24 マサチューセッツ インスティテュート オブ テクノロジー Encapsulation of tissue cells and their use in peptide scaffolds
DE10113712A1 (en) * 2001-03-16 2002-09-26 Lifebits Ag Data carrier, to take chemical and especially bio-chemical substances for the identification of reactions, as a gene chip, has CD structure of pits formed by defined points of non-mirrored surfaces to take the substances
DE10113708A1 (en) * 2001-03-16 2002-09-19 Lifebits Ag Applying reagents to measurement bearer pits involves aligning stamp relative to bearer and bringing stamp into contact with bearer, whereby reagent remains on corresponding bearer pits
US7338613B2 (en) * 2001-09-10 2008-03-04 Surface Logix, Inc. System and process for automated microcontact printing
WO2003065120A2 (en) * 2002-01-11 2003-08-07 Massachusetts Institute Of Technology Microcontact printing
EP1490520A4 (en) * 2002-03-12 2006-06-07 Surface Logix Inc Assay device that analyzes the absorption, metabolism, permeability and/or toxicity of a candidate compound
US6890654B2 (en) * 2002-04-18 2005-05-10 Northwestern University Encapsulation of nanotubes via self-assembled nanostructures
US7361731B2 (en) 2002-05-20 2008-04-22 Genencor International, Inc. Peptide derivatives, and their use for the synthesis of silicon-based composite materials
CA2485177C (en) 2002-05-20 2012-03-06 Dow Corning Corporation Synthesis of inorganic structures using templation and catalysis by self assembled repeat protein polymers
JP2004069677A (en) * 2002-06-13 2004-03-04 Canon Inc Immunological measuring method, reagent for immunological measurement, and its manufacturing method
US20040067544A1 (en) * 2002-06-27 2004-04-08 Viola Vogel Use of adhesion molecules as bond stress-enhanced nanoscale binding switches
US20050112432A1 (en) * 2002-08-27 2005-05-26 Jonah Erlebacher Method of plating metal leafs and metal membranes
CA2496777A1 (en) * 2002-08-29 2004-05-06 Bioscale, Inc. Resonant sensor and sensing system
AU2003272310A1 (en) * 2002-09-11 2004-04-30 The Cleveland Clinic Foundation Ultrafiltration membrane, device, bioartificial organ and methods
WO2004042060A1 (en) * 2002-11-08 2004-05-21 University Of Copenhagen Method of immobilising a protein to a zeolite
JP2004179274A (en) * 2002-11-26 2004-06-24 Hitachi Ltd Optical semiconductor device
GB0321937D0 (en) * 2003-09-19 2003-10-22 Univ Liverpool Nanoparticle conjugates and method of production thereof
US20050214377A1 (en) * 2004-03-24 2005-09-29 Sanjay Mistry Microparticles for cell delivery
US7648844B2 (en) * 2005-05-02 2010-01-19 Bioscale, Inc. Method and apparatus for detection of analyte using an acoustic device
US7611908B2 (en) * 2005-05-02 2009-11-03 Bioscale, Inc. Method and apparatus for therapeutic drug monitoring using an acoustic device
US7749445B2 (en) * 2005-05-02 2010-07-06 Bioscale, Inc. Method and apparatus for analyzing bioprocess fluids
US7300631B2 (en) * 2005-05-02 2007-11-27 Bioscale, Inc. Method and apparatus for detection of analyte using a flexural plate wave device and magnetic particles
US7464580B2 (en) * 2005-09-26 2008-12-16 Oakland University Ionic liquid high temperature gas sensors
US7886577B2 (en) 2006-03-30 2011-02-15 Oakland University Devices with surface bound ionic liquids and method of use thereof
US8375768B2 (en) * 2006-03-30 2013-02-19 Oakland University Ionic liquid thin layer sensor for electrochemical and/or piezoelectric measurements
US9403126B2 (en) 2007-01-10 2016-08-02 The Regents Of The University Of Michigan Ultrafiltration membrane, device, bioartificial organ, and related methods
CN101054409B (en) * 2007-05-09 2010-09-01 四川大学 Amphiphilic short peptide and use thereof
JP5587772B2 (en) 2007-06-27 2014-09-10 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Oligopeptide tyrosinase inhibitors and uses thereof
CA2728140C (en) 2007-06-27 2019-09-03 The Board Of Trustees Of The Leland Stanford Junior University Peptide tyrosinase inhibitors and uses thereof
US8354280B2 (en) * 2007-09-06 2013-01-15 Bioscale, Inc. Reusable detection surfaces and methods of using same
KR100894703B1 (en) * 2007-10-29 2009-04-24 서강대학교산학협력단 Methods for immobilizing cells
DE102009021876A1 (en) * 2009-05-19 2010-11-25 Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. Analyzing neurite outgrowth, comprises depositing neuron and neuron-like cell on substrate having grid pattern with first- and second region on which neuron and neuron-like cell accumulate, where first region is surrounded by second region
US8741833B2 (en) 2010-07-16 2014-06-03 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
US8546338B2 (en) 2010-12-08 2013-10-01 Johnson & Johnson Consumer Companies, Inc. Self-assembling hydrogels based on dicephalic peptide amphiphiles
IT202000004528A1 (en) * 2020-03-04 2021-09-04 Carmen Lammi Self-assembling peptides

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5330911A (en) * 1989-09-28 1994-07-19 Board Of Regents, The University Of Texas System Surfaces having desirable cell adhesive effects
US5384263A (en) * 1987-10-13 1995-01-24 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US5512131A (en) * 1993-10-04 1996-04-30 President And Fellows Of Harvard College Formation of microstamped patterns on surfaces and derivative articles
US5527681A (en) * 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5541070A (en) * 1987-10-13 1996-07-30 Kauvar; Lawrence M. Method to identify and characterize candidate drugs
US5620850A (en) * 1994-09-26 1997-04-15 President And Fellows Of Harvard College Molecular recognition at surfaces derivatized with self-assembled monolayers
US6329209B1 (en) * 1998-07-14 2001-12-11 Zyomyx, Incorporated Arrays of protein-capture agents and methods of use thereof
US20020072074A1 (en) * 1997-06-25 2002-06-13 Massachusetts Institute Of Technology Self-assembling peptide surfaces for cell patterning and interactions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
EP0812434B1 (en) 1995-03-01 2013-09-18 President and Fellows of Harvard College Microcontact printing on surfaces and derivative articles
AU6774996A (en) 1995-08-18 1997-03-12 President And Fellows Of Harvard College Self-assembled monolayer directed patterning of surfaces
US6319227B1 (en) * 1998-08-05 2001-11-20 Scimed Life Systems, Inc. Automatic/manual longitudinal position translator and rotary drive system for catheters

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5384263A (en) * 1987-10-13 1995-01-24 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US5541070A (en) * 1987-10-13 1996-07-30 Kauvar; Lawrence M. Method to identify and characterize candidate drugs
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5527681A (en) * 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5330911A (en) * 1989-09-28 1994-07-19 Board Of Regents, The University Of Texas System Surfaces having desirable cell adhesive effects
US5512131A (en) * 1993-10-04 1996-04-30 President And Fellows Of Harvard College Formation of microstamped patterns on surfaces and derivative articles
US5620850A (en) * 1994-09-26 1997-04-15 President And Fellows Of Harvard College Molecular recognition at surfaces derivatized with self-assembled monolayers
US20020072074A1 (en) * 1997-06-25 2002-06-13 Massachusetts Institute Of Technology Self-assembling peptide surfaces for cell patterning and interactions
US6329209B1 (en) * 1998-07-14 2001-12-11 Zyomyx, Incorporated Arrays of protein-capture agents and methods of use thereof

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020094572A1 (en) * 1993-10-04 2002-07-18 Rahul Singhvi Method of formation of microstamped patterns of plates for adhesion of cells and other biological materials, devices and uses therefor
US7067306B2 (en) 1993-10-04 2006-06-27 President & Fellows Of Harvard College Device containing cytophilic islands that adhere cells separated by cytophobic regions
US7993905B2 (en) 1993-10-04 2011-08-09 President And Fellows Of Harvard College Device containing cytophilic islands that adhere cells separated by cytophobic regions
US20090011493A1 (en) * 1993-10-04 2009-01-08 President And Fellows Of Harvard College Device containing cytophilic islands that adhere cells separated by cytophobic regions
US20080291141A1 (en) * 2005-03-11 2008-11-27 Searete Llc. Elements for self assembling displays
US20060202944A1 (en) * 2005-03-11 2006-09-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Elements for self assembling displays
US8334819B2 (en) 2005-03-11 2012-12-18 The Invention Science Fund I, Llc Superimposed displays
US20070030220A1 (en) * 2005-03-11 2007-02-08 Searete Llc Self assembling display with substrate
US8300007B2 (en) 2005-03-11 2012-10-30 The Invention Science Fund I, Llc Self assembling display with substrate
US9299274B2 (en) 2005-03-11 2016-03-29 Deep Science, Llc Elements for self assembling displays
US9153163B2 (en) 2005-03-11 2015-10-06 The Invention Science Fund I, Llc Self assembly of elements for displays
US8284120B2 (en) 2005-03-11 2012-10-09 The Invention Science Fund I, Llc Self assembly of elements for displays
US8711063B2 (en) 2005-03-11 2014-04-29 The Invention Science Fund I, Llc Self assembly of elements for displays
US8669703B2 (en) 2005-03-11 2014-03-11 The Invention Science Fund I, Llc Self assembly of elements for displays
US8382544B2 (en) 2005-03-11 2013-02-26 The Invention Science Fund I, Llc Method of repairing a display assembled on a substrate
US8390537B2 (en) 2005-03-11 2013-03-05 The Invention Science Fund I, Llc Method of assembling displays on substrates
US8570482B2 (en) 2005-03-11 2013-10-29 The Invention Science Fund I, Llc Self assembly of elements for displays
US20100019991A1 (en) * 2005-03-11 2010-01-28 Searete Llc Superimposed displays
US20060202943A1 (en) * 2005-03-11 2006-09-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Self assembly of elements for displays
US20100065188A1 (en) * 2005-03-11 2010-03-18 Searete Llc Self assembly of elements for displays
US20100128069A1 (en) * 2005-03-11 2010-05-27 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method of assembling displays on substrates
US8508434B2 (en) 2005-03-11 2013-08-13 The Invention Science Fund I, Llc Superimposed displays
US7662008B2 (en) 2005-04-04 2010-02-16 Searete Llc Method of assembling displays on substrates
US20060220989A1 (en) * 2005-04-04 2006-10-05 Hillis W D Method of assembling displays on substrates
US8860635B2 (en) 2005-04-04 2014-10-14 The Invention Science Fund I, Llc Self assembling display with substrate
US20060220988A1 (en) * 2005-04-04 2006-10-05 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Self assembling display with substrate
US7990349B2 (en) 2005-04-22 2011-08-02 The Invention Science Fund I, Llc Superimposed displays
US20060238464A1 (en) * 2005-04-22 2006-10-26 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Superimposed displays
US9327010B2 (en) 2005-04-25 2016-05-03 Massachusetts Institute Of Technology Compositions and methods for promoting hemostasis and other physiological activities
US9162005B2 (en) 2005-04-25 2015-10-20 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
US11839694B2 (en) 2005-04-25 2023-12-12 Massachusetts Institute Of Technology Compositions and methods for promoting hemostasis and other physiological activities
US20090111734A1 (en) * 2005-04-25 2009-04-30 Massachusetts Institute Of Technology Compositions and methods for promoting hemostasis and other physiological activities
US9789157B2 (en) 2005-04-25 2017-10-17 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
US9364513B2 (en) 2005-04-25 2016-06-14 Maasachusetts Institute of Technology Compositions and methods for promoting hemostasis and other physiological activities
US20070203062A1 (en) * 2005-04-25 2007-08-30 Rutledge Ellis-Behnke Compositions and methods for promoting hemostasis and other physiological activities
US20080032934A1 (en) * 2005-04-25 2008-02-07 Clear Nano Solutions Compositions for prevention of adhesions and other barrier applications
US20080133641A1 (en) * 2005-08-01 2008-06-05 Gent Robert Paul Van Methods for publishing content
US20080091233A1 (en) * 2006-04-25 2008-04-17 Massachusetts Institute Of Technology Compositions and methods for affecting movement of contaminants, bodily fluids or other entities, and/or affecting other physiological conditions
US10137166B2 (en) 2006-04-25 2018-11-27 Massachusetts Institute Of Technology Compositions and methods for affecting movement of contaminants, bodily fluids or other entities, and/or affecting other physiological conditions
US9084837B2 (en) 2006-04-25 2015-07-21 Massachusetts Institute Of Technology Compositions and methods for affecting movement of contaminants, bodily fluids or other entities, and/or affecting other physiological conditions
US10682386B2 (en) 2006-04-25 2020-06-16 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
US9511113B2 (en) 2006-04-25 2016-12-06 Massachusetts Institute Of Technology Compositions and methods for affecting movement of contaminants, bodily fluids or other entities, and/or affecting other physiological conditions
US20080032425A1 (en) * 2006-08-03 2008-02-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method of assembling displays on substrates
US7977130B2 (en) 2006-08-03 2011-07-12 The Invention Science Fund I, Llc Method of assembling displays on substrates
US9415084B2 (en) 2007-03-14 2016-08-16 Arch Biosurgery, Inc. Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
US20080274979A1 (en) * 2007-03-14 2008-11-06 Rutledge Ellis-Behnke Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
US20110236261A1 (en) * 2008-12-11 2011-09-29 Koninklijke Philips Electronics N.V. Sensing device for detecting target elements in a fluid
US9439941B2 (en) 2009-12-14 2016-09-13 The University Of Hong Kong Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells
US9821022B2 (en) 2013-08-22 2017-11-21 Arch Biosurgery, Inc. Implantable meshes for controlling the movement of fluids
US10314886B2 (en) 2013-08-22 2019-06-11 Arch Biosurgery, Inc. Implantable meshes for controlling the movement of fluids
US9339476B2 (en) 2013-08-22 2016-05-17 Arch Biosurgery, Inc. Implantable meshes for controlling the movement of fluids
US10869907B2 (en) 2013-08-22 2020-12-22 Arch Biosurgery, Inc. Implantable meshes for controlling the movement of fluids

Also Published As

Publication number Publication date
WO1998058967A1 (en) 1998-12-30
US6368877B1 (en) 2002-04-09
US20020072074A1 (en) 2002-06-13
US20060019309A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
US6368877B1 (en) Self-assembling peptide surfaces for cell patterning and interactions
Veiseh et al. Guided cell patterning on gold–silicon dioxide substrates by surface molecular engineering
Mrksich et al. Using self-assembled monolayers to understand the interactions of man-made surfaces with proteins and cells
US10927406B2 (en) Microarray system and a process for detecting target analytes using the system
Davis et al. Immobilization of RGD to< 1 1 1> silicon surfaces for enhanced cell adhesion and proliferation
Zhang et al. Biological surface engineering: a simple system for cell pattern formation
Castellana et al. Solid supported lipid bilayers: From biophysical studies to sensor design
AU740877B2 (en) Composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces
Yap et al. Protein and cell micropatterning and its integration with micro/nanoparticles assembly
US20050048570A1 (en) Structured-functional bonding matrices for biomolecules
JP2002541458A (en) Miniaturized cell array method and apparatus for cell-based screening
US7658994B2 (en) Substrates and compounds bonded thereto
JP2008525763A (en) Three-dimensional nanostructured and microstructured support
Groll et al. Ultrathin coatings from isocyanate terminated star PEG prepolymers: patterning of proteins on the layers
KR20060113747A (en) Substrates and compounds bonded thereto
US20040171053A1 (en) Molecular microarrays and methods for production and use thereof
LaGraff et al. Scanning force microscopy and fluorescence microscopy of microcontact printed antibodies and antibody fragments
Shakeri et al. Biofunctional interfaces for cell culture in microfluidic devices
WO2007115444A1 (en) Seperation or analysis composition comprising active nanostructure and seperation or analysis method
CA2435894C (en) End group activated polymers with oligonucleotide ligands
US20060084159A1 (en) Method for manufacturing of three dimensional composite surfaces for microarrays
US20070259382A1 (en) Rapid localized cell trapping on biodegradable polymers
Vélez Biofunctionalized Surfaces
Krsko et al. Electron-beam patterning of biological molecules
KR20080017738A (en) Nanoarray protein chip and the method for preparing thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION